Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Regeneron Pharmaceuticals Inc patents


Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors


Methods and compositions for targeted genetic modifications and methods of use

Methods and compositions are provided for generating targeted genetic modifications on the y chromosome or a challenging target locus. Compositions include an in vitro culture comprising an xy pluripotent and/or totipotent animal cell (i.e., xy es cells or xy ips cells) having a modification that decreases the level and/or activity of an sry protein; and, culturing these cells in a medium that promotes development of xy f0 fertile females. ... Regeneron Pharmaceuticals Inc

Anti-il-33 antibodies and uses thereof

The present invention provides antibodies that bind to interleukin-33 (il-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate il-33-mediated signaling. ... Regeneron Pharmaceuticals Inc

Non-human animals having a humanized cluster of differentiation 47 gene

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (cd) gene, in particular a humanization of a cd47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous cd47 gene so that said non-human animals express a cd47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).. ... Regeneron Pharmaceuticals Inc

Amino acid acylation reagents and methods of using the same

Provided herein are compounds useful for appending amino acids to nucleophiles.. . ... Regeneron Pharmaceuticals Inc

Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

The present invention provides pharmaceutical compositions comprising a vegf antagonist and an anti-ctla-4 antibody, and methods of use thereof. The compositions and methods of the present invention are useful for the treatment of cancers and other diseases and disorders in which anti-angiogenic therapies and/or targeted immune responses may be beneficial.. ... Regeneron Pharmaceuticals Inc

Radiolabeled anti-lag3 antibodies for immuno-pet imaging

Radiolabeled anti-lag3 antibodies and their use in immuno-pet imaging are provided herein. Included are methods of detecting the presence of lag3 proteins in a patient or sample.. ... Regeneron Pharmaceuticals Inc

Taurine supplemented cell culture medium and methods of use

The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to serum-free media or chemically-defined media to increase the production of a protein of interest. ... Regeneron Pharmaceuticals Inc

Anti-asic1 antibodies and uses thereof

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (asic1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, asic1-mediated ion currents in cells expressing human asic1. ... Regeneron Pharmaceuticals Inc

Inducible eukaryotic expression system

Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. ... Regeneron Pharmaceuticals Inc

Hsd17b13 variants and uses thereof

Provided are compositions related to hsd17b13 variants, including isolated nucleic acids and proteins related to variants of hsd17b13, and cells comprising those nucleic acids and proteins. Also provided are methods related to hsd17b13 variants. ... Regeneron Pharmaceuticals Inc

Hsd17b13 variants and uses thereof

Provided are compositions related to hsd17b13 variants, including nucleic acid molecules and polypeptides related to variants of hsd17b13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to hsd17b3 variants. ... Regeneron Pharmaceuticals Inc

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation. ... Regeneron Pharmaceuticals Inc

Compositions and methods for reducing bioburden in chromatography

The invention provides methods for microbial bioburden reduction of various chromatography matrices, including bioburden reduction in the context of large-scale protein a-based affinity chromatography columns.. . ... Regeneron Pharmaceuticals Inc

Human antibodies to s. aureus hemolysin a toxin

The present invention provides antibodies that bind to staphylococcus aureus hemolysin a toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to hemolysin a. ... Regeneron Pharmaceuticals Inc

07/26/18 / #20180208656

Anti-prokineticin receptor (prokr) antibodies and uses thereof

The present invention provides antibodies that bind to prokineticin receptors (prokrs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human prokr1 and/or prokr2. ... Regeneron Pharmaceuticals Inc

07/26/18 / #20180206962

Rotatable surgical table

Provided is a rotatable surgical apparatus and accompanying method for processing a specimen via the rotatable surgical apparatus. The surgical apparatus may include a base member and a platform member where the platform member and base member abut. ... Regeneron Pharmaceuticals Inc

07/26/18 / #20180206462

Non-human animals having a humanized programmed cell death 1 gene

Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a programmed cell death 1 (pdcd1) gene. The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous pdcd1 gene so that the non-human animals express a pd-1 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).. ... Regeneron Pharmaceuticals Inc

07/19/18 / #20180201991

Systems and methods for sequencing t cell receptors and uses thereof

Disclosed herein are methods and systems that can reconstruct, extract, and/or analyze tcr sequences using short reads. The methods and systems can be applied to both single cell and bulk sequencing data.. ... Regeneron Pharmaceuticals Inc

07/12/18 / #20180194841

Methods for tumor treatment using cd3xcd20 bispecific antibody

The present invention relates to a method (dosage regimen) for administering a cd3×cd20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating b cell (cd20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a cd3×cd20 bispecific antibody to a human patient. ... Regeneron Pharmaceuticals Inc

07/05/18 / #20180186883

Human antibodies to pd-l1

The present invention provides antibodies that bind to the t-cell co-inhibitor ligand programmed death-ligand1 (pd-l1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-l1. ... Regeneron Pharmaceuticals Inc

07/05/18 / #20180186869

High affinity human antibodies to human angiopoietin-2

The present invention provides antibodies that bind to angiopoietin-2 (ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ang-2. ... Regeneron Pharmaceuticals Inc

07/05/18 / #20180185668

Human antibodies to pd-1

The present invention provides antibodies that bind to the t-cell co-inhibitor programmed death-1 (pd-1) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to pd-1. ... Regeneron Pharmaceuticals Inc

07/05/18 / #20180185504

Methods of treating prlr positive breast cancer

Provided herein are methods of treating prolactin receptor positive breast cancer using an antibody drug conjugate (adc) comprising an anti-prlr antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent. In certain embodiments, the anti-prlr antibody or antigen-binding fragment thereof is conjugated to maytansinoid. ... Regeneron Pharmaceuticals Inc

06/28/18 / #20180179288

High affinity human antibodies to human il-4 receptor

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (il-4r). Also provided are expression vectors comprising nucleic acid molecule that encode anti-il-4r antibodies, host cells comprising the expression vectors, and methods of producing anti-il-4r antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.. ... Regeneron Pharmaceuticals Inc

06/21/18 / #20180171006

Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a

The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein. ... Regeneron Pharmaceuticals Inc

06/14/18 / #20180162924

Fusion polypeptides capable of activating receptors

A fusion polypeptide comprising (a)x-m-(a′)y, wherein a and a′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. ... Regeneron Pharmaceuticals Inc

06/14/18 / #20180161464

Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging

Radiolabeled anti-pd-l1 antibodies and their use in immuno-pet imaging are provided herein. Included are methods of detecting the presence of pd-l1 proteins in a patient or sample.. ... Regeneron Pharmaceuticals Inc

06/14/18 / #20180160663

Genetically modified mouse whose genome comprises a humanized cd274 gene

Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a cluster of differentiation 274 (cd274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous cd274 gene so that said non-human animals express a programmed cell death ligand 1 (pd-l1) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).. ... Regeneron Pharmaceuticals Inc

06/07/18 / #20180155436

Methods of treating inflammatory conditions

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of il-33 and il-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an il-33 antagonist alone or in combination with one or more therapeutically effective doses of an il-4r antagonist. ... Regeneron Pharmaceuticals Inc

06/07/18 / #20180155416

Anti-activin a antibodies and uses thereof

The present invention provides antibodies that bind to activin a and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to activin a with high affinity. ... Regeneron Pharmaceuticals Inc

06/07/18 / #20180155408

Vegf antagonist formulations suitable for intravitreal administration

Ophthalmic formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. ... Regeneron Pharmaceuticals Inc

06/07/18 / #20180155389

Steroids and protein-conjugates thereof

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (gcs) to cells.. . ... Regeneron Pharmaceuticals Inc

05/31/18 / #20180147280

Method of averting opioid addiction

A method of averting opioid addiction in a patient is disclosed. The method can be applied to a patient suffering from moderate to severe low back pain (lbp). ... Regeneron Pharmaceuticals Inc

05/24/18 / #20180139941

Non-human animals having a humanized signal-regulatory protein gene

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a sirpα gene. Genetically modified mice are described, including mice that express a human or humanized sirpα protein from an endogenous sirpα locus.. ... Regeneron Pharmaceuticals Inc

05/24/18 / #20180139940

Humanized t cell mediated immune responses in non-human animals

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized t cell co-receptor (e.g., humanized cd4 and/or cd8 (e.g., cd8α and/or cd8β)), a human or humanized t cell receptor (tcr) comprising a variable domain encoded by at least one human tcr variable region gene segment and/or a human or humanized major histocompatibility complex that binds the humanized t cell co-receptor (e.g., human or humanized mhc ii (e.g., mhc ii α and/or mhc ii β chains) and/or mhc i (e.g., mhc i α) respectively, and optionally human or humanized β 2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. ... Regeneron Pharmaceuticals Inc

05/17/18 / #20180134794

Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof

Provided herein are antibodies and bispecific antigen-binding molecules that bind met and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human met. ... Regeneron Pharmaceuticals Inc

05/17/18 / #20180134781

Methods of treating obesity with anti-angptl8 antibodies

The present invention provides antibodies that bind to angptl8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-angptl8 antibodies that bind human angptl8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase hdl-c, in a subject.. ... Regeneron Pharmaceuticals Inc

05/10/18 / #20180127508

Antigen-binding proteins that antagonize leptin receptor

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and antagonize lepr signaling. ... Regeneron Pharmaceuticals Inc

05/10/18 / #20180125043

Non-human animals having an engineered immunoglobulin lambda light chain locus

Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human igλ light chains, in whole or in part. ... Regeneron Pharmaceuticals Inc

05/03/18 / #20180118852

Recombinant cell surface capture proteins

Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (poi) that has an immunoglobulin ch3 domain and/or substituted ch3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. ... Regeneron Pharmaceuticals Inc

05/03/18 / #20180118848

Anti-muc16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind muc16 and cd3, and uses thereof

Mucin 16 (muc16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human igg antibodies that bind to human and muc16 (monospecific antibodies). ... Regeneron Pharmaceuticals Inc

05/03/18 / #20180116192

Humanized il-15 animals

Genetically modified non-human animals comprising a humanized interleukin-15 (il-15) gene. Cells, embryos, and non-human animals comprising a human il-15 gene. ... Regeneron Pharmaceuticals Inc

05/03/18 / #20180116190

Genetically modified major histocompatibility complex mice

The invention provides genetically modified non-human animals that express chimeric human/non-human mhc i and mhc ii polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. ... Regeneron Pharmaceuticals Inc

04/19/18 / #20180104357

Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

The protein known as six-transmembrane epithelial antigen of prostate 2 (steap2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human igg antibodies that bind to human steap2 (monospecific antibodies). ... Regeneron Pharmaceuticals Inc

04/12/18 / #20180099049

Room temperature stable lyophilized protein

Stable lyophilized therapeutic protein compositions and their methods of manufacture are provided. Specifically, the use of water as a solid cake plasticizer and protein stabilizer is described. ... Regeneron Pharmaceuticals Inc

04/05/18 / #20180094267

Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus

A non-human animal (e.g., a rodent) model for diseases associated with a c9orf72 heterologous hexanucleotide repeat expansion sequence is provided, which non-human animal comprises a heterologous hexanucleotide repeat (ggggcc) in an endogenous c9orf72 locus. A non-human animal disclosed herein comprising a heterologous hexanucleotide repeat expansion sequence comprising at least one instance, e.g., repeat, of a hexanucleotide (ggggcc) sequence may further exhibit a characteristic and/or phenotype associated with one or more neurodegenerative disorders (e.g., amyotrophic lateral sclerosis (als) and/or frontotemporal dementia (ftd), etc.). ... Regeneron Pharmaceuticals Inc

04/05/18 / #20180094070

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen. ... Regeneron Pharmaceuticals Inc

04/05/18 / #20180094069

Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen. ... Regeneron Pharmaceuticals Inc

04/05/18 / #20180094066

Anti-prlr antibodies and uses thereof

The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity. ... Regeneron Pharmaceuticals Inc

03/29/18 / #20180084768

Humanized t cell co-receptor mice

The invention provides genetically modified non-human animals that express chimeric human/non-human t cell co-receptor polypeptides (e.g., cd4, cd8α, cd8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.. ... Regeneron Pharmaceuticals Inc

03/08/18 / #20180064078

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. ... Regeneron Pharmaceuticals Inc

03/01/18 / #20180057583

Anti-il-25 antibodies and uses thereof

The present invention provides antibodies that bind to human interleukin-25 (il-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human il-25 with high affinity. ... Regeneron Pharmaceuticals Inc

03/01/18 / #20180057580

Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-gremlin-1 (grem1) antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (pah).. . ... Regeneron Pharmaceuticals Inc

02/22/18 / #20180051066

Modified chimeric polypeptides with improved pharmacokinetic properties

The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component.. ... Regeneron Pharmaceuticals Inc

02/15/18 / #20180044436

Stabilized formulations containing anti-pcsk9 antibodies

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (pcsk9). The formulations may contain, in addition to an anti-pcsk9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. ... Regeneron Pharmaceuticals Inc

02/08/18 / #20180037910

Nuclease-mediated targeting with large targeting vectors

Compositions and methods are provided for making one or more targeted genetic modifications at a target genomic locus by employing homologous recombination facilitated by single or double-strand break at or near the target genomic locus. Compositions and methods for promoting efficiency of homologous recombination between an ltvec and a target genomic locus in prokaryotic or eukaryotic cells using engineered nucleases are also provided.. ... Regeneron Pharmaceuticals Inc

02/08/18 / #20180036406

Anti-erbb3 antibodies and uses thereof

The present invention provides antibodies that bind to erbb3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human erbb3. ... Regeneron Pharmaceuticals Inc

02/08/18 / #20180036405

Anti-egfr antibodies and uses thereof

The present invention provides antibodies that bind to egfr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human egfr with high affinity. ... Regeneron Pharmaceuticals Inc

02/01/18 / #20180030480

Novel cho integration sites and uses thereof

Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. ... Regeneron Pharmaceuticals Inc

02/01/18 / #20180030114

Gpr156 variants and uses thereof

The disclosure provides nucleic acids, including cdna, comprising alterations that encode aspartic acid at a position corresponding to position 533 of the human g protein-coupled receptor 156 protein (gpr156). The disclosure also provides isolated and recombinant human gpr156 protein variants that comprise an aspartic acid at a position corresponding to position 533. ... Regeneron Pharmaceuticals Inc

02/01/18 / #20180030099

Apelin fusion proteins and uses thereof

The invention provides a fusion protein or polypeptide comprising an apelin peptide fused to a multimerizing component. The invention also provides a fusion protein or polypeptide comprising an apelin peptide fused to an fc domain, a fragment of an fc domain, or a variant of an fc domain. ... Regeneron Pharmaceuticals Inc

02/01/18 / #20180027782

Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

Provided are non-human animals comprising a mutation in the fbn1 gene to model neonatal progeroid syndrome with congenital lipodystrophy (npscl). Also provided are methods of making such non-human animal models. ... Regeneron Pharmaceuticals Inc

01/18/18 / #20180016343

Methods for treating or preventing asthma by administering an il-4r antagonist

The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (il-4r) antagonist, such as an anti-il-4r antibody.. ... Regeneron Pharmaceuticals Inc

01/18/18 / #20180016324

Anti-zika virus antibodies and methods of use

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to zikv glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing zikv activity, thus providing a means of treating or preventing zikv infection in humans. ... Regeneron Pharmaceuticals Inc

01/18/18 / #20180015185

Mice expressing polymorphic low affinity fcgammar alpha-chains

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity fcγr locus, and wherein the mouse is capable of expressing a functional fcrγ-chain. Genetically modified mice are described, including mice that express low affinity human fcγr genes from the endogenous fcγr locus, and wherein the mice comprise a functional fcrγ-chain. ... Regeneron Pharmaceuticals Inc

01/11/18 / #20180008672

Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension

The present invention provides anti-activin a antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hypertension (pah).. . ... Regeneron Pharmaceuticals Inc

01/04/18 / #20180002708

Nuclease-mediated dna assembly

Methods are provided herein for assembling at least two nucleic acids using a sequence specific nuclease agent (e.g., a grna-cas complex) to create end sequences having complementarity and subsequently assembling the overlapping complementary sequences. The nuclease agent (e.g., a grna-cas complex) can create double strand breaks in dsdna in order to create overlapping end sequences or can create nicks on each strand to produce complementary overhanging end sequences. ... Regeneron Pharmaceuticals Inc

01/04/18 / #20180002426

Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies

The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hil-4r). The formulations may contain, in addition to an anti-hil-4r antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. ... Regeneron Pharmaceuticals Inc

01/04/18 / #20180000056

Humanized il-4 and il-4ra animals

Non-human animals comprising a human or humanized il-4 and/or il-4rα nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous il-4 gene and/or il-4rα gene with a human il-4 gene and/or il-4rα gene in whole or in part, and methods for making and using the non-human animals, are described. ... Regeneron Pharmaceuticals Inc

12/28/17 / #20170369593

Mice expressing a limited immunoglobulin light chain repertoire

A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. ... Regeneron Pharmaceuticals Inc

12/28/17 / #20170367308

Non-human animals expressing ph-sensitive immunoglobulin sequences

Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more cdrs, in an n-terminal region, and/or in a loop 4 region are also provided. ... Regeneron Pharmaceuticals Inc

12/21/17 / #20170360930

Vegf antagonist formulations

Formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of seq id no:4.. ... Regeneron Pharmaceuticals Inc

12/21/17 / #20170360013

Animal model for dry eye and methods of use of such animals

Provided herein are methods for creating an animal model for the study of dry eye and methods of using such animal models to test candidate treatments for ocular conditions and determine the efficacy of such treatments.. . ... Regeneron Pharmaceuticals Inc

12/14/17 / #20170355774

Anti-gitr antibodies and uses thereof

Provided herein are antibodies, and antigen-binding fragments thereof that specifically bind glucocorticoid-induced tumor necrosis factor receptor (gitr) and methods of using the same, including, e.g., methods of treatment using the same.. . ... Regeneron Pharmaceuticals Inc

12/14/17 / #20170355757

Anti-c5 antibodies and uses thereof

The present invention provides monoclonal antibodies that bind to the complement factor 5 (c5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to c5 protein. ... Regeneron Pharmaceuticals Inc

12/14/17 / #20170355751

Human antibodies to ebola virus glycoprotein

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing ebola virus activity, thus providing a means of treating or preventing ebola virus infection in humans. ... Regeneron Pharmaceuticals Inc

12/07/17 / #20170347633

Non-human animals expressing exogenous terminal deoxynucleotidyltransferase

Provided herein are methods and compositions related to non-human animals that express exogenous terminal deoxynucleotidyltransferase (tdt).. . ... Regeneron Pharmaceuticals Inc

11/30/17 / #20170340728

Human antibodies to middle east respiratory syndrome - coronavirus spike protein

The present invention provides monoclonal antibodies that bind to the middle east respiratory syndrome—coronavirus (mers-cov) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to mers-cov spike protein. ... Regeneron Pharmaceuticals Inc

11/23/17 / #20170335341

Efficient selectivity of recombinant proteins

The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on gpt genes of mammalian origin. ... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332611

Humanized c5 animals

Non-human animals comprising a human or humanized c3 and/or c5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous c5 gene and/or c3 gene with a human or humanized c5 gene and/or c3 gene, and methods for making and using the non-human animals, are described. ... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332610

Methods for breaking immunological tolerance using multiple guide rnas

Methods and compositions are provided for making non-human animals with reduced tolerance of a foreign antigen of interest and making antigen-binding proteins against that foreign antigen of interest using such animals. The methods and compositions employ crispr/cas9 systems using multiple guide rnas to reduce or eliminate expression of a self-antigen homologous to or sharing an epitope of interest with the foreign antigen of interest or to reduce or eliminate expression of an epitope on the self-antigen that is shared with the foreign antigen of interest.. ... Regeneron Pharmaceuticals Inc

11/23/17 / #20170332609

Humanized light chain mice

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an adam6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.. . ... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327593

Method for generating high affinity antibodies

The present disclosure relates to a method for identifying cells that express antigen-specific antibodies with a high binding affinity for a monomeric antigen. Using fluorescence activated cell sorting, cells expressing high affinity antigen-specific antibodies are selected from a population of immune cells isolated from a mammal that has been immunized with or otherwise exposed to the antigen. ... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327590

Methods of treating skin cancer by administering a pd-1 inhibitor

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (pd-1) antagonist (e.g., an anti-pd-1 antibody). ... Regeneron Pharmaceuticals Inc

11/16/17 / #20170327567

Combination of anti-pd-1 antibodies and radiation to treat cancer

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., solid tumors). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (pd-1) antagonist (e.g., an anti-pd-1 antibody), optionally, in combination with radiation therapy. ... Regeneron Pharmaceuticals Inc

11/09/17 / #20170320948

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation. ... Regeneron Pharmaceuticals Inc

10/26/17 / #20170308642

Non-hypergeometric overlap probability

Methods, software, and systems are provided for determining the probability of an overlap set of entities having an overlap size, where the overlap set is independently selected from two sets of non-identical entities. Applications of the invention to microarrays are provided. ... Regeneron Pharmaceuticals Inc

10/12/17 / #20170291938

Production cell line enhancers

The present invention relates to discovery of the ectopic expression of edem2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell, the cho cell, containing recombinant polynucleotides encoding edem2. ... Regeneron Pharmaceuticals Inc

10/12/17 / #20170291937

Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (angptl8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (angptl3). ... Regeneron Pharmaceuticals Inc

10/12/17 / #20170290308

Rodents having a humanized tmprss gene

Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent tmprss gene, such as an endogenous rodent tmprss2, tmprss4, or tmprss11d gene.. ... Regeneron Pharmaceuticals Inc

10/05/17 / #20170286594

Genetic variant-phenotype analysis system and methods of use

Methods and systems for generating and analyzing genetic variant-phenotype association results are disclosed.. . ... Regeneron Pharmaceuticals Inc

10/05/17 / #20170281725

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-vegf therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. ... Regeneron Pharmaceuticals Inc

09/28/17 / #20170273286

Genetically modified major histocompatibility complex animals

The invention provides genetically modified non-human animals that express a humanized mhc ii protein (humanized mhc ii α and β polypeptides), as well as embryos, cells, and tissues comprising the humanized mhc ii protein. Also provided are constructs for making, and methods of making, the genetically modified non-human animals. ... Regeneron Pharmaceuticals Inc

09/21/17 / #20170265442

Non-human animals having a humanized signal-regulatory protein gene

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a sirpα gene. Genetically modified mice are described, including mice that express a human or humanized sirpα protein from an endogenous sirpα locus.. ... Regeneron Pharmaceuticals Inc

09/14/17 / #20170260544

Compositions and methods for modifying cells

A method for engineering and utilizing large dna vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large dna targeting vectors for eukaryotic cells, termed ltvecs, are derived from fragments of cloned genomic dna larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. ... Regeneron Pharmaceuticals Inc

09/14/17 / #20170260293

Multivalent antigen-binding proteins

Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. ... Regeneron Pharmaceuticals Inc

09/14/17 / #20170258059

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. ... Regeneron Pharmaceuticals Inc

09/07/17 / #20170253666

Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (pcsk9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (angptl3). ... Regeneron Pharmaceuticals Inc

09/07/17 / #20170252434

Compositions for improving the health related quality of life of rheumatoid arthritis patients

The present invention provides compositions and methods of for improving the health-related quality of life of a subject suffering from rheumatoid arthritis, comprising administering to the subject an effective amount of sarilumab.. . ... Regeneron Pharmaceuticals Inc

08/31/17 / #20170247474

Multivalent antigen-binding proteins

Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. ... Regeneron Pharmaceuticals Inc

08/31/17 / #20170247436

Non-human animals having a mutant kynureninase gene

Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a mutant l-kynurenine hydrolase (or kynureninase) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification in an endogenous kynureninase gene so that said non-human animals express a kynureninase polypeptide that includes an amino acid substitution that results in the elimination of an epitope in said kynureninase polypeptide that is present in the membrane proximal external region of human immunodeficiency virus-1 gp41.. ... Regeneron Pharmaceuticals Inc

08/31/17 / #20170245482

Rodents having a humanized tmprss gene

Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent tmprss gene, such as an endogenous rodent tmprss2, tmprss4, or tmprss11d gene.. ... Regeneron Pharmaceuticals Inc

08/31/17 / #20170245481

Non-human animals having a engineered angptl8 gene

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an angiopoietin-like protein 8 (angptl8) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous angptl8 locus so that said non-human animals express a human angptl8 polypeptide.. ... Regeneron Pharmaceuticals Inc

08/24/17 / #20170241887

Isolating cells expressing secreted proteins

A method of detecting and isolating cells that produce a secreted protein of interest (poi) that has an immunoglobulin ch3 domain and/or substituted ch3 domain, comprising: a) constructing a cell line transiently or stably expressing a cell surface capture molecule, which binds the poi, by transfecting the cell line with a nucleic acid that encodes such cell surface capture molecule; b) transfecting said cell simultaneously or subsequently with a second nucleic acid that encodes a poi wherein such poi is secreted; c) detecting the surface-displayed poi by contacting the cells with a detection molecule, which binds the poi; and d) isolating cells based on the detection molecule.. . ... Regeneron Pharmaceuticals Inc

08/24/17 / #20170239342

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. ... Regeneron Pharmaceuticals Inc

08/17/17 / #20170233806

Methods and systems for detection of abnormal karyotypes

Methods and systems for detecting abnormal karyotypes are disclosed. An example method can comprise determining read coverage data, allele balance distributions of heterozygous snps, and chromosomal segments where heterozygosity is not observed. ... Regeneron Pharmaceuticals Inc

08/17/17 / #20170233466

Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3

The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (angptl3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. ... Regeneron Pharmaceuticals Inc

08/10/17 / #20170226231

Mice that make vl binding proteins

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain v gene segments, d gene segments, and j gene segments with at least one light chain v gene segment and at least one light chain j gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. ... Regeneron Pharmaceuticals Inc

08/10/17 / #20170226197

Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a

The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein. ... Regeneron Pharmaceuticals Inc

08/10/17 / #20170223939

Mice that make vl binding proteins

Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain v gene segments, d gene segments, and j gene segments with at least one light chain v gene segment and at least one light chain j gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. ... Regeneron Pharmaceuticals Inc

08/03/17 / #20170218399

Production of fertile xy female animals from xy es cells

Methods and compositions are described for making phenotypically female fertile animals from xy donor cells and suitable host embryos. Culture media and methods are provided for maintaining xy donor cells in culture that after introduction into a host embryo and gestation in a suitable host will result in fertile xy female animals. ... Regeneron Pharmaceuticals Inc

08/03/17 / #20170218065

Anti-glucagon antibodies and uses thereof

The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human gcg with high affinity. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170211115

Fucosylation-deficient cells

An isolated nucleic acid encoding an fx protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified fx protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170211099

Methods and compositions for modifying a targeted locus

Methods and compositions are provided for modifying one or more target loci in a cell. Such methods comprise providing a cell comprising a first polynucleotide encoding a first selection marker operably linked to a first promoter active in the cell, wherein the first polynucleotide further comprises a first recognition site for a first nuclease agent. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170210813

Anti-pdgfr-beta antibodies and uses thereof

The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170210800

Aplnr modulators and uses thereof

The present invention provides apelin receptor (aplnr) modulators that bind to aplnr and methods of using the same. The invention includes aplnr modulators such as antibodies, or antigen-binding fragments thereof, which inhibit or attenuate aplnr-mediated signaling. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170210790

Human antibodies to fel d1 and methods of use thereof

The present invention provides antibodies that bind to the cat allergen, fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to fel d1. ... Regeneron Pharmaceuticals Inc

07/27/17 / #20170209591

Maytansinoid derivatives, conjugates thereof, and methods of use

Provided herein are maytansinoid compounds, derivatives thereof, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.. . ... Regeneron Pharmaceuticals Inc

07/20/17 / #20170204430

Targeted modification of rat genome

Compositions and methods are provided for modifying a rat genomic locus of interest using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Compositions and methods for generating a genetically modified rat comprising one or more targeted genetic modifications in their germline are also provided. ... Regeneron Pharmaceuticals Inc

07/20/17 / #20170202911

Use of a vegf antagonist to treat angiogenic eye disorders

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a vegf antagonist to a patient. The methods of the present invention include the administration of multiple doses of a vegf antagonist to a patient at a frequency of once every 8 or more weeks. ... Regeneron Pharmaceuticals Inc

07/06/17 / #20170191101

Clarification of mammalian cell culture

Disclosed is an improved method for clarifying a cell culture during the manufacture of a protein. The method includes the step of transiently reducing the ph of a cell culture, followed by a holding step for a period of time, followed by the neutralization of the cell culture prior to clarification by centrifugation.. ... Regeneron Pharmaceuticals Inc

07/06/17 / #20170191014

Systems and trays for processing samples by a robotic platform

A system for processing samples by a robotic platform has a tray that defines a well defining a drain. The well has a bottom surface, an access port in fluid communication with the drain, and an insert adapted to be received in the well. ... Regeneron Pharmaceuticals Inc

07/06/17 / #20170188556

Non-human animals having a humanized b-cell activating factor gene

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized b-cell activating factor gene. Non-human animals and cells that express a human or humanized b-cell activating factor protein from an endogenous b-cell activating factor locus are described.. ... Regeneron Pharmaceuticals Inc

06/29/17 / #20170181978

Polymer protein microparticles

Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.. ... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174789

Anti-tie2 antibodies and uses thereof

The present invention provides antibodies that bind to tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human tie2 and block the interaction between tie2 and one or more tie2 ligands such as angiopoietin 1 (ang1), angiopoietin 2 (ang2), angiopoietin 3 (ang3) and/or angiopoietin 4 (ang4). ... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174781

Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of acute lymphoblastic leukemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds to cd20 and cd3.. ... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174779

Combination of anti-pd-1 antibodies and anti-cd20/anti-cd3 antibodies to treat cancer

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a b-cell cancer such as hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (pd-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to cd20 and cd3.. ... Regeneron Pharmaceuticals Inc

06/22/17 / #20170174769

Fgf21 receptor agonists and uses thereof

The present invention provides agonists of fgf21 signaling. In particular, the present invention provides fgf21 receptor (fgf21r) agonists that are capable of simultaneously binding βklotho (klb) and/or fgfr1c to mimic the signaling activity of fgf21. ... Regeneron Pharmaceuticals Inc

06/15/17 / #20170166646

Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hil-6r).. . ... Regeneron Pharmaceuticals Inc

06/15/17 / #20170164590

Genetically modified major histocompatibility complex mice

The invention provides genetically modified non-human animals that express chimeric human/non-human mhc i polypeptide and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. ... Regeneron Pharmaceuticals Inc

06/15/17 / #20170164588

Non-human animals expressing humanized cd3 complex

Non-human animals, expressing humanized cd3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized cd3 proteins are also provided. ... Regeneron Pharmaceuticals Inc

05/18/17 / #20170135329

Genetically modified major histocompatibility complex mice

The invention provides genetically modified non-human animals that express a humanized mhc ii protein (humanized mhc ii α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. ... Regeneron Pharmaceuticals Inc

05/11/17 / #20170129960

Human antibodies to the glucagon receptor

The present invention provides antibodies that bind to the human glucagon receptor, designated gcgr and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gcgr. ... Regeneron Pharmaceuticals Inc

05/04/17 / #20170121413

Antibody-drug conjugates, their preparation and their therapeutic use

The present disclosure relates to conjugates comprising biologically active molecules linked to a multimeric antigen-binding compound or a multimeric immunoglobulin via a linker. The disclosure further provides reagents and methods of manufacturing the conjugates and the linkers. ... Regeneron Pharmaceuticals Inc

04/27/17 / #20170112107

Humanized dipeptidyl-peptidase iv (dpp4) animals

Non-human animals comprising a human or humanized dpp4 nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous dpp4 gene with a human or humanized dpp4 gene, or non-human animals comprising a human or humanized dpp4 gene in addition to the endogenous dpp4 gene are described. ... Regeneron Pharmaceuticals Inc

04/20/17 / #20170107484

Human lambda light chain mice

Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. ... Regeneron Pharmaceuticals Inc

04/13/17 / #20170101477

Antigen-binding proteins that activate the leptin receptor

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and activate lepr signaling. ... Regeneron Pharmaceuticals Inc

04/13/17 / #20170101472

Anti-lag3 antibodies and uses thereof

The present invention provides antibodies that bind to the t cell co-inhibitor lymphocyte activation gene 3 (lag3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to lag3. ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170096681

Enhanced expression and stability regions

Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (eesyrs) are provided for expression of a gene of interest in a eukaryotic cell. ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170096496

Anti-pcsk9 antibodies with ph-dependent binding characteristics

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hpcsk9) characterized by the ability to reduce serum ldl cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum hdl cholesterol and/or with little or no measurable effect on liver function, as determined by alt and ast measurements.. . ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170096491

Human antibodies to human tnf-like ligand 1a (tl1a)

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human tnf-like ligand 1a (htl1a) is provided. The human anti-htl1a antibodies are useful in treating diseases or disorders associated with tl1a, such as inflammatory diseases or disorders, e.g., inflammatory bowel diseases, including ulcerative colitis and crohn's disease, rheumatoid arthritis, and the like; autoimmune diseases or disorders, such as multiple sclerosis, diabetes, and the like; and allergic reactions, such as asthma and allergic lung inflammation.. ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170096488

Human antibodies to gfr alpha3 and methods of use thereof

The present invention provides antibodies that bind to human gfrα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human gfrα3. ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170096483

Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof

The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an il-33 mediated disease or disorder and who are more likely to respond to therapy with an il-33 antagonist. The invention also relates to methods of treatment of an il-33-mediated disease or disorder in a patient by administering an il-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. ... Regeneron Pharmaceuticals Inc

04/06/17 / #20170094955

Humanized rodents that express heavy chains containing vl domains

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an adam6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.. . ... Regeneron Pharmaceuticals Inc

03/30/17 / #20170088622

Anti-tie2 antibodies and uses thereof

The present invention provides antibodies that bind to tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human tie2 and block the interaction between tie2 and one or more tie2 ligands such as angiopoietin 1 (ang1), angiopoietin 2 (ang2), angiopoietin 3 (ang3) and/or angiopoietin 4 (ang4). ... Regeneron Pharmaceuticals Inc

03/30/17 / #20170086432

Non-human animals having humanized fc-gamma receptors

Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an fcγri protein.. . ... Regeneron Pharmaceuticals Inc

03/23/17 / #20170080086

Methods and formulations for treating vascular eye diseases

The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (ang-2) inhibitor such as an anti-ang-2 antibody in combination with a vascular endothelial growth factor (vegf) antagonist (e.g., aflibercept).. ... Regeneron Pharmaceuticals Inc

03/23/17 / #20170079250

Production of fertile xy female animals by silencing of genes on the y chromosome

Methods and compositions are provided for generating f0 fertile xy female animals. The methods and compositions involve making xy pluripotent or totipotent animal cells, in vitro cell cultures, or embryos that are capable of producing a fertile female xy animal in an f0 generation. ... Regeneron Pharmaceuticals Inc

03/16/17 / #20170073407

Vegf antagonist formulations

Formulations of a vascular endothelial growth factor (vegf)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of seq id no:4.. ... Regeneron Pharmaceuticals Inc

03/09/17 / #20170067078

Methods and compositions for the targeted modification of a genome

Compositions and methods are provided for modifying a genomic locus of interest in a eukaryotic cell, a mammalian cell, a human cell or a non-human mammalian cell using a large targeting vector (ltvec) comprising various endogenous or exogenous nucleic acid sequences as described herein. Further methods combine the use of the ltvec with a crispr/cas system. ... Regeneron Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###